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ABBREVIATIONS 
ANC – Absolute Neutrophil Count 
Chemo RT - Chemoradiotherapy 
CMF – Cyclophosphamide, Methotrexate, 5- Flurouracil  
DHAP – Dexamethasone, Cytosine- Arabinoside, Cisplatinum 
FAC- 5 - Fluro uracil, Adriamycin , Cyclophosphamide 
FEC – 5 - Fluro uracil, Epirubicin, Cyclophosphamide 
FEC –D -  5 – Flurouracil, Epirubicin, Cyclophosphamide- Docetaxol 
FN- Febrile neutropenia 
G-CSF – Colony stimulating factor 
ICE – Ifhosfamide, Carboplatin, Etoposide 
ICU – Intensive Care Unit 
LDH – Lactate Dehydrogenase 
PS – Performance Status 
TMP-SMZ-- trimethoprim–sulfamethoxazole 
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INTRODUCTION 
With the advent of cytotoxic therapy for cancer especially the intensified 
dose regimens used in haematological cancer and solid tumors, occurrence of febrile 
neutropenia poses a major problem in treating this patient population.  Though fever 
and infection as a consequence of neutropenia, in cancer patients were first described 
about 100 years ago still bacterial infections are life threatening complications in 
patients with severe, persistent neutropenia. Without preventive measures, 48% to 
60% of febrile neutropenic patients have an infection, while 16% to 20% of 
profoundly neutropenic patients (neutrophil counts <0.1 x 10
9 
 cells/L) develop  
bacteraemia . Neutropenia leads to increased hospitalisation, increased costs and loss 
of quality of life. Most dreadful complication of febrile neutropenia is mortality 
which ranges from 2 to 21% in various studies.
1
  
                   To prevent chemotherapy-related FN, prophylactic antibiotics and 
granulocyte colony-stimulating factor (G-CSF) have been applied successfully. 
Earlier Studies evaluating prophylaxis with trimethoprim–sulfamethoxazole (TMP-
SMZ) demonstrated a reduced infection rate for patients treated with TMP-SMZ 
when compared with placebo or no treatment.
1
 However with the decreasing efficacy 
of TMP-SMZ  in modern times  fluroquinolones  have emerged as a good alternative 
for prophylaxis in febrile neutropenia. When quinolones are used for prevention of 
infection in neutropenic patients, the rate of Gram-negative bacteraemia is reduced to 
1–2%.  The advantages of using fluroquinolones are: they are orally absorbable, have 
broad antimicrobial spectrum and also have some activity against gram positive 
organisms and it is cost –effective. The main problem with chemoprophylaxis is the 
emergence of resistance especially to Escherichia coli; however, since the antibiotics 
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used for chemoprophylaxis in cancer patients are widely used in the community, it is 
unlikely that their use in neutropenic patients will significantly aggravate the overall 
situation.
2 
Many drugs in the fluroquinolone group such has ciprofloxacin, 
moxifloxacin and levofloxacin has been tried as prophylaxis in febrile neutropenia in 
various studies across the world. Gatifloxacin has not been tried in vivo in the 
chemoprophylaxis of febrile neutropenia. Also there is a paucity of studies related to 
the prophylaxis in febrile neutropenia in our country where the disease burden is 
substantial when compared to the western countries. In this background this study is 
attempted to assess the clinical evidence supporting the efficacy of antibiotic 
prophylaxis with fluoroquinolones in neutropenic cancer patients. 
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AIM OF THE STUDY 
 
• To assess the clinical evidence and impact  supporting the efficacy  of 
antibiotic prophylaxis with fluoroquinolones  in neutropenic breast 
carcinoma  patients. 
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REVIEW OF LITERATURE 
           Definition of febrile neutropenia 
 Fever: A single oral temperature of greater than 38.3°C  (101°F)  or  38.0°C 
or greater (100.4°F) for over 1 hour. 
 Neutropenia: absolute neutrophil count less than 500 mcL or less than 1,000 
mcL with predicted rapid decline in 48 hrs. 
 50% of febrile patients will have no documentation of infection. 20% will 
have clinically positive infection and 30% have microbiologically (culture  
positive ) documented infection. 
3
 
Fever is an indicator of infection, even though other causes of fever can  be 
present  eg. drug fever or fever due to malignancy itself, blood products etc. 
However fever due to neutropenia should be considered seriously because 
infection develops and progresses rapidly in neutropenic patients which 
sometimes may be fatal .
4
 
Incidence of febrile neutropenia in chemotherapy regimens in breast carcinoma 
patients 
               On the basis of the regimens used and their reported febrile neutropenia 
(FN) rates, the incidence of FN among women receiving chemotherapy for node-
positive early-stage breast cancer is estimated at around 16%.  It is roughly estimated 
that more than 1000 women in UK who receives chemotherapy for node positive 
breast cancer will   have febrile neutropenia. 
5
 
6 
 
PACS trial compared 6 cycles of  FEC combination chemotherapy  with 3 
cycles of FEC followed with Docetaxol. The incidence of grade 3 and 4 neutropenia 
is 10.9% and 20.2 %  in FEC and FEC-D combination chemotherapy respectively 
where as incidence of FN is 8.4% and 11.2%.  . The authors noted  that even though 
docetaxol had higher incidence of FN , most of the episodes occurred only in  first 
cycle .
6
 
  David et al , conducted  a phase II  trial  where 60  locally advanced breast 
carcinoma patients received 5 cycles of  Taxol- Epirubicin combination neoadjuvant 
chemotherapy . They reported the incidence of febrile neutropenia as 16%. However 
no death or life threatening infections was reported.
7 
             Moon et al in their study of 82 locally advanced breast cancer patients 
treated with FAC neoadjuvant chemotherapy  where by 5- Flurouracil was given as 
continous infusion showed the incidence of grade 3 and 4 neutropenia  as 36%.One 
patient had pneumonia with sepsis.
8
 
   In a randomnised trial ,  FAC combination chemotherapy was compared with 
Vinorelbine – Doxorubicin combination in metastatic breast carcinoma patients . The 
incidence of grade 3\ 4 neutropenia  and febrile neutropenia  was 7% and 25%  
respectively in  both arms .
9 
 
             Ismaili et al compared 2 groups of breast carcinoma patients who received 
concurrent chemoradiotherapy  as adjuvant therapy. One group received  
Anthracycline based chemotherapy ( FEC-75, FAC-50 ) and another group CMF 
combination chemotherapy. Rate of grade 3 and 4 neutropenia was 9.3% and 6.2% 
respectively and grade 2\3 anemia  was also more in the anthracycline arm .
10 
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History of febrile neutropenia 
First description of febrile neutropenia was given by Bodey and colleagues 
even  before 3 decades. He observed 52 leukemic patients at National Cancer 
Institute and found out  that severe infections occurred when neutrophils count is less 
than 1000 per  cubic mm. He proposed an association between infection, fever and 
fall in neutrophil counts.
11
 
In the management of febrile neutropenia , the scientific basis for doublet 
antibiotic usage  was proposed by Schimpff and colleagues. They observed 75 
leukemic patients who had febrile  neutropenia. The most common organism isolated 
from them was Pseudomonas aueruginosa. These patients were treated with 
empirical antibiotic combination carbenicillin and gentamicin . These patients had 
better outcome than those patients treated with single agent gentamicin in the same 
year.
12
 
Pizzo  and colleagues proposed the role  of antifungals  by adding 
Amphotericin-B  if neutopenic fever continues more than 7 days. By adding 
antifungals , mortality and incidence of septic shock drastically decreased. 13 
Risk factors for febrile neutropenia 
Risk factors  for febrile neutropenia may be patient related,  tumour related,  
treatment  related or  laboratory abnormalities 
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Patient related risk factors 
 Age 
       Advanced age is a risk factor for severity of neutropenia and its  complications. 
Usually they have comorbids and poor general condition.  Their tolerance to 
chemotherapy is poor. Often elderly aged patients are treated with lesser dose of 
chemotherapy to minimize chemotherapy related toxicities.
14
 
 Poor performance status and comorbidities  
Poor performance status , comorbidities  such as renal, cardiac, liver disease, 
chronic obstructive pulmonary disease , systemic hypertension , diabetes mellitus 
has shown in various studies to increase the duration and severity of FN .This  can 
lead  to  prolonged hospitalisation and death.
15
 
Tumour related risk factors 
Comparing solid and haematological cancer patients, latter patients have 
higher risk of neutropenic complications and death, due to the reasons of disease 
process itself and greater intensity of treatment.
16
 In solid malignancies patients with 
advanced disease are more prone for febrile neutropenia which may be due to poor 
performance status, bone marrow involvement, immunosuppression etc.
17
 
Treatment related risk factors 
         Another risk factor for febrile neutropenia is the intensity of chemotherapy 
regimens. Some regimens are more myelosuppressive than others. Eg  DHAP, ICE 
salvage regimens used in Non Hodgkins Lymphoma  , BEACOPP regimen in 
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Hodgkins lymphoma , high dose anthracycline regimens in breast carcinoma 
patients.
17
 
Laboratory Abnormalities 
                 Hemogram and biochemical values may predict the severity of disease,   
co-morbidities and impact of cytotoxic chemotherapy. If the pre-treatment 
hemoglobin is less than 12 gm, it predicts severe neutropenia. 
18
 In another study,   
patients with non Hodgkins lymphoma treated with CHOP chemotherapy , having 
pre-treatment albumin of less than 3.5 gm and LDH greater than upper limit of 
normal served as significant predictors of  higher chance of febrile neutropenia.
19 
Risk Models for Predicting Chemotherapy-Induced Neutropenia 
       For the last 10 years several investigators have identified subset of post 
chemotherapy patients who are at low risk for febrile neutropenia. These patients can 
be given outpatient treatment for the febrile episode or early discharge from the 
hospital so that they can continue treatment in home. Kern et.al and Freifeld et al 
conducted two large randomised trials and showed efficacy and safety of empirical 
oral antibiotic ( ciprofloxacin and amoxicillin plus clauvulanate ) compared with 
parenteral antibiotic in these low risk patients. 
20
 
       In various studies, definition of low risk is not uniform. To define low risk, 
Talcott et al conducted a retrospective study, where by 261 medical records of 184 
cancer patients were reviewed. He classified them in to 4 groups , out of that 3 
groups had significant  higher risk than the remaining patient group whom seems to 
be at lower risk..They proposed patients with no comorbids and controlled cancer are 
at lower risk with expected medical complications less than 5%.  
21
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        Multinational Association of Supportive Care in Cancer (MASCC) conducted a 
prospective study in febrile neutropenic  patients  to develop a scoring system to 
identify low risk individuals. Definition of low risk according to MASCC is those 
having a high probability of fever resolution without development of serious medical 
complications or death. The following factors such as  burden of illness, 
hypotension, chronic obstructive pulmonary disease, solid tumor or no previous 
fungal infection in hematologic malignancies, age, outpatient status and dehydration 
were taken into account. On  validation , a MASCC score of  ≥ 21 identified low-risk 
patients with a positive predictive value of 91%, specificity of 68%, and sensitivity 
of 71%. 
22 
Grading of neutropenia. 
Adverse 
Event 
Grade 0 
(In Cu.mm) 
Grade I 
(InCu.mm) 
Grade II 
(InCu.mm) 
Grade III 
(In Cu.mm) 
Grade Iv 
(In Cu.mm ) 
Total Count WNL < LLN – 
3000 
> 2000- 
<3000 
>1000-
<2000 
<1000 
Neutrophil 
Count 
WNL >1500-
>2000 
>1000-
<1500 
> 500-
<1000 
<500 
Febrile 
Neutropenia 
0 - - Present Life-
Threatening 
Sepsis 
NCI COMMON TOXICITY CRITERIA 
22 
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Consequences of febrile neutropenia. 
Dose Delays and Reductions  
Lymann et al  in a retrospective  study  to assess practice patterns  of  
adjuvant chemotherapy for early-stage breast cancer,   observed treatment delay of 
greater than 7 days in 24.9% patients and dose reduction of greater than 15% 
occurred in 36.5% patients due to neutropenia, About two thirds of patients received 
relative dose intensity less than 85%. Patient who were at greater risk are obese , 
older, patients not on primary G-CSF prophylaxis  and three drug combination 
regimens. 
23
 Bonnadonna et al have estimated that patients who receive less than 
65% of their planned dose have been shown to have survival rates similar to those 
who receive no chemotherapy at all.  
24
 
 
Mortality 
            Most dreadful complication of febrile neutropenia is mortality. Caggiano et al 
estimated that in febrile neutropenic patients who are hospitalised the mortality 
ranges from 3.4%-10.5% with overall mortality of 6.8% 
25
  whereas Smith et al and 
Herbst et al have shown a range from 2 to 21% .
26
  Lyman et al observed that  the 
higher rates are often seen in patients with  age related comorbidities, or in patients 
with poor performance status, patients with  advanced cancer and those who are 
undergoing palliative chemotherapy .The highest mortality rates were observed for 
lung carcinoma followed by  leukemias  and then gastric carcinomas. 
27
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Hospitalisation due to neutropenia. 
               In cancer patients, neutropenic hospitalisation is around 7.83 per 1000 
individuals . Hematological malignancies constituted the highest number of hospital 
admission ie. 43 per 1000 individuals with cancer. In solid malignancies, incidence 
of neutropenic hospitalisation in descending order was seen in cancer of  pancreas, 
lung, ovary and stomach. In breast cancer  patients neutropenic hospitalisation is 
around 4.9% .
28
  
Caggiano et al observed that the mean length of   hospital stay was 9.2 ± 10.4 
days. The average cost of neutropenic hospitalization was $13,372 ± $21,000. As 
expected leukemia patients had high mean length of hospital stay and cost of 
neutropenic hospitalisation where as in solid tumours both were highest in gastric 
carcinoma. They also observed that even though, in solid tumours duration of 
hospital stay and cost is less than haematological malignancies incidence of 
mortality is almost the same. Authors concluded by saying neutropenic 
hospitalisation is a common and expensive condition with associated mortality in 
approximately 1 in 14 hospitalized cancer patients. Hospitalisation puts patients at 
risk of developing further complications, such as hospital-acquired infections and 
thromboembolic events, which add to the overall cost of FN 
29,30
 
 
 
Increased Costs 
             Moore and Crom  have observed that occurrence of febrile neutropenia in 
patients lead to increased direct and indirect costs to the individual, the health 
providing system and the national economy. The costs are due to a range of factors, 
including hospitalization for treatment of FN, significant morbidity and mortality, 
13 
 
financial losses for patients and their families / carers and reduced health-related 
quality of life .These increased  costs also undermine public confidence in cancer 
services . 
31
 Holmes et al have reported that in UK, FN imposes a significant burden 
on National Health Services finances and resources and a single episode is estimated 
to cost the NHS £3582 which is due to hospitalization, which on average is 6 – 8 
days..  Hospital acquired infections and thromboembolic events add to the overall 
cost of FN.
32
 
 
Quality of Life 
Okon et al
33
 have observed that development of FN has been indirectly 
shown to correlate with lower quality-of-life scores and Glaspy et al
34
 have shown an  
an increase in the incidence and severity of chemotherapy-related side effects such as 
mucositis, abdominal pain and diarrhea, anorexia and fatigue with development of 
FN. FN also causes disruption of  normal life such as childcare and employment 
leading to financial and social implications for patients and their families.(Moore and 
Crom) .
31
 
 
STRATEGIES TO PREVENT FEBRILE NEUTROPENIA 
1. Modification of the chemotherapy regimen 
2. Use of growth factors & maintenance of  chemotherapy dose  intensity 
3. Prophylactic  antibiotics 
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Modification of the chemotherapy regimen 
Chemotherapy dose reductions and treatment delays are common practices. 
Lyman and colleagues reviewed several randomized trials and concluded that a large 
percentage of patients—approximately half—receive less than half of their initially 
planned chemotherapy but in practice this strategy reduces the disease free and 
overall survival benefit.
27 
 
Use of growth factors 
A phase III study conducted by Martin et al  analysed the toxicity and health 
related quality of life  of breast cancer patients treated with FAC (5-fluorouracil, 
doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, 
cyclophosphamide) with and without primary prophylactic G-CSF (PPG). They 
evaluated 1047 patients and found that addition of GCSF significantly reduced the 
incidence of febrile neutropenia. In addition it was found to reduce other side effects 
of TAC chemotherapy such as grade 2–4 anaemia, asthenia, anorexia, nail disorders, 
stomatitis, myalgia and dysgeusia.
35
 
Jack Webster conducted a pilot study in 19 patients with newly diagnosed 
breast cancer receiving adjuvant systemic chemotherapy who met criteria for dose 
reduction or treatment delay due to neutropenia based on a rationale that relatively 
short courses of G-CSF may reduce the need for a reduction in chemotherapy dose or 
a delay in treatment for patients at risk for FN, thus permitting administration of full-
dose intensity systemic chemotherapy. All the patients received human G-CSF at a 
dose of 5 µg/kg daily administered subcutaneously in a nonrandomized fashion 
15 
 
beginning seven to 10 days following chemotherapy. The authors found that after 
initiating G-CSF, chemotherapy doses were reduced in only three patients (16%), 
and treatment was delayed in six patients (31%) and a significant difference in the 
proportion of patients experiencing treatment delays was observed (P<.05). Also 
differences in the mean ANC in pre GCSF and post GCSF showed a rising trend 
with each week of chemotherapy. They concluded that breast cancer patients 
receiving standard adjunctive chemotherapy who meet criteria for dose reduction or 
treatment delay can safely continue on full-dose intensity chemotherapy using 
relatively short courses of G-CSF.
36
 
A randomized phase III study investigated the role of the addition of primary 
G-CSF prophylaxis to primary antibiotic prophylaxis in Small cell lung carcinoma 
patients who were at risk of FN because of either  elderly age, poor performance 
status, Co- morbid , and / or previous chemotherapy treatment. 175 patients were 
accrued and randomly assigned for treatment with cyclophosphamide, doxorubicin, 
and etoposide (CDE), followed by prophylactic antibiotics alone (ciprofloxacin and 
roxithromycin) or by antibiotics in combination with G-CSF on days 4 to 13. There 
was a 50% reduction in the incidence of FN in cycle 1 with the addition of GCSF to 
antibiotics when compared to antibiotics group( 10 vs 20 patients respectively , P 
=0.01). In patients with FN during 1
st
 cycle there was marginal difference between 
the two groups in regard to the duration of an episode of FN (median, 4 v 3 days), the 
duration of hospital admission for FN (median, 10 v 6 days), and the duration of 
therapeutic antibiotics needed because of FN (median, 7 v 8 days). Duration of 
hospital admission (all causes) in cycle 1 was shorter in the antibiotics plus G-CSF 
group compared with the antibiotics-only group, due to the difference in incidence of 
16 
 
FN (mean, 5.7 v 2.7 days). However it was similar in both groups in cycles 2 -5. The 
median delivered dose intensity of cyclophosphamide   and doxorubicin for cycles 
actually delivered was statistically significantly higher in the antibiotics plus G-CSF 
arm, but the absolute difference was only 7.0 and 0.2 mg/m
2
/wk, respectively.
37
 
Role of antibiotic prophylaxis 
Another method to decrease febrile neutropenia is the prophylactic use of 
antibiotics especially quinolones but there is a concern that it will give rise to the 
emergence of   resistant gram negative organisms.  In an attempt to settle the 
controversy of the role of  prophylactic antibacterial agents after
 
chemotherapy , 
Michael Cullen and his colleagues  conducted a randomized, double-blind, placebo-
controlled
 
trial in 1565  patients who were receiving cyclic chemotherapy for
 
solid 
tumors such as breast cancer, lung cancer, testicular cancer or lymphoma and who 
were at risk for temporary,
 
severe neutropenia (fewer than 500 neutrophils per cubic 
millimeter).Patients were randomly given levofloxacin 500mg once daily or a 
placebo for the seven days during the expected neutropenic period. The primary 
outcome was the
 
incidence of clinically documented febrile episodes (temperature
 
of 
more than 38°C) attributed to infection. 
The authors observed that during the first cycle of chemotherapy and the 
entire course of chemotherapy less percentage of   patients in levofloxacin group had 
documented febrile episodes than the patients in the placebo group. Also the 
occurrence of probable infection and also the severe infection was less in 
levofloxacin group when compared with the placebo group. In addition 
hospitalization was required for
 
the treatment of infection less often in levofloxacin 
17 
 
group. Thus the authors concluded that among patients receiving chemotherapy for 
solid
 
tumors or lymphoma, the prophylactic use of levofloxacin reduces
 
the incidence 
of fever, probable infection, and hospitalization. 
38 
Antibiotic prophylaxis to cover gram positive organisms 
          With the increased use of quinolones and intense dose chemotherapy which 
leads to severe mucositis , there was higher incidence of gram positive infections. It 
contributed to 20 – 30% of episodes of febrile neutropenia. 39 Various agents such as 
penicillin, macrolides and vancomycin which are active against gram positive 
organisms were used for prophylaxis with positive results. 
40
  
EORTC conducted a  double-blind placebo-controlled phase III study in 
which patients with small cell lung cancer were given standard dose CDE or 
intensified CDE chemotherapy and were also randomized to receive prophylactic 
antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, bid, days 4-13) or a 
placebo. The incidence of febrile neutropenia during the first cycle and through all 
the cycles were less in the antibiotics arm than in the placebo arm .(11% vs 25% in 
1
st
 cycle and 24% vs 43% in all cycles).  There were less Gram-positive (12 vs. 4), 
Gram-negative (20 vs. 5) and clinically documented (38 vs. 15) infections in the 
antibiotics arm which was attributed to quinolones group and macrolide group of 
antibiotic. The days of hospitalization was reduced and thus the use of therapeutic 
antibiotics in the antibiotic arm when compared to the placebo group. However, the 
overall number of days of hospitalization was not reduced (P = 0.05). Death due to 
infection occurred only in the placebo arm: 6% of all placebo patients vs. 0% of 
antibiotic arm   patients (P = 0.022)  representing 10% of placebo patients who 
developed fever. However patients in the antibiotic arm suffered from the adverse 
18 
 
effects of the drug such as grade 2-3 nausea, mucositis and diarrhoea. Thus the 
authors concluded that prophylactic ciprofloxacin plus roxithromycin during CDE 
chemotherapy reduced the incidence of febrile neutropenia, the number of infections, 
the use of therapeutic antibiotics and hospitalizations due to febrile neutropenia by 
approximately 50% with reduced number of infectious deaths.
41
 
 
Emergence of resistant gram negative bacteremia. 
One of the most potential complication of quinolone prophylaxis is the 
emergence of resistant gram negative infections. Giampaola et al conducted a trial in 
Italy involving 35 centers with 760 patients randomnised to levofloxacin and 
placebo. They noted that antibiotic prophylaxis had substantially reduced the 
incidence of febrile neutropenia.   However there was 3% incidence of   levofloxacin 
resistant gram negative bacilli in antibiotic group when compared with 1% incidence 
in placebo group.
42
 Michael and his associates , in a span of four years observed  35 
episodes of Escherichia coli bacteremia in a series of 230 cases of bacteremia in 
neutropenic patients with cancer of which thirteen episodes (37%) were due to 
quinolone-resistant strains. They also identified that prophylaxis with norfloxacin 
was the only factor which was significantly associated with the development of 
quinolone-resistant E. coli bacteremia as all the 13 patients with bacteremia due to 
resistant strains received norfloxacin (P < .001). They concluded that cancer patients 
with febrile neutropenia may be at risk of developing E.coli bacteremia due to 
quinolone resistant strain when given fluroquinolone prophylaxis.
43
  
              Reuter et al conducted a prospective study by discontinuing quinolone 
prophylaxis and studied the incidence of febrile neutropenia , bacteraemia and 
19 
 
mortality in patients with neutropenia after chemotherapy. The study was stopped 
prematurely since there was higher incidence of febrile episodes and mortality. They 
also noticed more gram negative bacteraemia  in discontinuation phase than base 
line. Once the antibiotic prophylaxis was introduced the number of febrile episodes , 
bacteraemia and mortality came down. 
44
 
Choice of drug 
Gafter –gvili et al conducted  a metanalysis on antibiotic prophylaxis in 
neutropenic patients . They identified 95 trials performed between 1973-1994. Out of 
these 95 trials, 52 trials used quinolone prophylaxis and 10 trials compared 
quinolones with trimethoprim- sulfhamethoxazole. Febrile episodes, bacteraemia and 
mortality were similar in both groups.  Indirect comparison of quinolone prophylaxis 
with placebo, showed a relative risk of 0.62 for all cause mortality where as it was 
0.71 when trimethoprim- sulfamethoxazole was compared with placebo. Norfloxacin 
was compared with placebo in 4 trials and no benefit was reported for mortality but 
Ciprofloxacin on comparison with no treatment in 6 trials showed all cause reduction 
of mortality.
45 
 
           Von Baum and his associates conducted a controlled before and after 
observational study with moxifloxacin prophylaxis in hemato-oncological patients. 
They compared this data with two periods of levofloxacin prophylaxis ie one a 
preceding period and another post-observational period. They observed a higher 
incidence of gram negative bacteremia per neutropenic episode especially due to 
enterococci  with moxifloxacin prophylaxis(11%) when compared with levofloxacin 
prophylaxis(6%).In patients who received moxifloxacin prophylaxis , 26 out of 30 
(87%) Gram negative bacteremias were caused by E.coli which were all 
20 
 
fluroquinolone resistant. With levofloxacin prophylaxis 14 out of 22 (64%) Gram-
negative bacteraemias in period 1 and 3 out of 3  Gram –negative bacteremias  in 
period 3 were caused by E. coli, all of these being fluoroquinolone resistant. Also a 
higher incidence of Clostridium difficle associated diarrhoea (43 cases) with an 
incidence of 33% per neutropenic episode was seen which was significantly higher 
than with prophylaxis with levofloxacin (6% for period 1, and 13% for period 3). 
They concluded that though newer fluroquinolones has high activity against 
anaerobes all fluroquinolones may not be equally beneficial in different therapeutic 
settings .Thus caution is required when choosing fluroquinolones for prophylaxis in 
neutropenic patients.
46
 
Marc Gurwith and his colleagues from USA conducted a trial in which they 
observed a reduction in the incidence of fever, parenteral antibiotic usage, and 
infections with gram-negative bacteria in hospitalized patients with neutropenia with 
administration of prophylactic trimethoprim – sulfamethoxazole (TMP –SMZ). They 
also observed that when antibiotics given prophylactically to adults had fewer 
hospitalizations for infection than the control group who were given placebo only 
when hospitalized. In children with acute leukemia, TMP-SMZ was effective in 
preventing bacterial and Pneumocystis carinii infections. Though prophylactic TMP 
and TMP-SMZ had equal efficacy and  incidence of side effects, TMP was less 
effective in suppressing gastrointestinal flora including TMP resistant gram negative 
rods and infections caused by  Pneumocystitis carinii. 
47
            
Hospitalisation and antibiotic prophylaxis 
Cullen et al in their study on antibiotic prophylaxis with levofloxacin in solid 
tumours and lymphoma had mentioned significant reduction in hospitalisation with 
21 
 
antibiotic prophylaxis. Benefit was more in first cycle when compared with other 
cycles ie., risk reduction of hospitalisation is 36% in first cycle against 27% across 
all cycles. Authors had shown prevention of  6 hospitalisations in each cycle  when 
prophylaxis was given to 100 patients. 
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Heijnen et al , on using roxithromycin and ciprofloxacin  as prophylaxis in 
small cell lung carcinoma  against placebo had shown the incidence of 
hospitalisation was 17% and 31% respectively. In this study intensified CDE  
combination chemotherapy was used. Also median days of hospital admission was 
significantly less in antibiotic group when compared with placebo ie., 4 vs 5 days. 
2% of patients in antibiotic group and 5% of patients in placebo group required 
intensive care support. Median days of admission in ICU was 2 and 7 days 
respectively.
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Mortality and antibiotic prophylaxis. 
Gafter et al carried out a meta-analysis  to find out whether antibiotic 
prophylaxis in neutropenic patients had any effect on decreasing the mortality. 92 
trials    were considered which met the inclusion criteria. Out of these 92 trials, 52 
trials had quinolone only prophylaxis. These trials include patients with both 
haematological and solid malignancies. They found out quinolone prophylaxis 
significantly decreases infection related and all cause mortality. Benefit of quinolone 
prophylaxis also extends in decreasing the episodes of febrile neutropenia, clinically 
\ microbiologically documented infections and bacteraemia. Number of fungal 
infections also did not differ between both the prophylaxis and placebo group.
45
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                             Mario et al conducted a meta analysis in which quinolones alone 
against quinlones with additional gram positive covering antibiotics were compared.                        
9 randomised trials which met the selection criteria were selected. They found out 
that doublet antibiotic regimen would have benefit in decreasing the number of 
febrile episodes but  however they had no effect on decreasing clinical documented 
infection and mortality. There were more side effects with combination antibiotics 
than with single agent quinolones. Since there was no clear cut benefit with gram 
positive coverage, authors were against the routine use of this strategy.
48 
 
In his meta-analysis, which consist of 2 parts , Reuel et al compared 
quinolone prophylaxis with control ( placebo, non absorbable antibiotic , co- 
trimoxazole) in first part  and in second part gram positive coverage  plus quinolone 
prophylaxis was compared  with controls. They concluded that both these methods 
had no effect on decreasing the mortality.
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Role of Gatifloxacin in febrile neutropenia 
In febrile neutropenia, gatifloxacin was used as a monotherapy in the 
treatment of low risk patients. Rolston et al conducted a study in which eligible 40 
adult low risk  ( breast cancer, sarcoma ) febrile neutropenia patients were started on 
oral gatifloxacin monotherapy. 95% of study population showed response to therapy. 
The mean time to defervescence of fever was around 4 days. Mean duration of usage 
of antibiotic was 7 days.
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Petrilli et al conducted a study in febrile neutropenic patients falling in the 
age group range of 3-21years and   having solid and haematological malignancies 
undergoing gatifloxacin monotherapy. Study involved 108 patients with 210 
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episodes. Nearly 75% had successful treatment. The mean duration of fever and 
antibiotic usage was 2.4 and 8.1 days respectively. No death was observed in the 
study. Authors concluded that gatifloxacin was an effective option in pediatric low 
risk febrile neutropenia patients.
51
 Hence gatifloxacin is used in the treatment of low 
risk febrile neutropenia especially in out- patient setting. 
 
Infections in febrile neutropenia 
 
Cullen et al had documented the foci of infection in the following sites in 
descending order: upper respiratory tract (24.1%) , lower respiratory tract 
(12.9%), skin and soft tissue  (10.5%) , urinary tract (8.3%) and  gastrointestinal 
tract (4.4%). Severe infections  as defined by the authors as severe sepsis related 
syndrome , death or both was observed in 1% and 2% of patients in Levofloxacin 
and placebo group respectively. 
 
The microbiologically documented infections in this study were less in 
antibiotic group when compared with placebo group (4.6% vs 12.6%). Bacteraemia 
was documented in 2.3% and 3.8%.
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Heijhen et al in their study on the prophylactic role of antibiotics by using 
Ciprofloxacin and Roxithromycin  documented clinically ,infections in 15 patients in 
antibiotic group and 35 in placebo group where as microbiologically documented 
infections was in 9 and 32 patients respectively. Respiratory and urinary tract 
infections was documented less in antibiotics group. 
41
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Gafter et al in their meta-analysis on studying the role of prophylactic 
antibiotics in reducing the infection associated mortality had documented lesser 
bacteraemia, clinically \ microbiologically documented infections, gram positive and 
negative infections with prophylactic antibiotics.
45
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METHODOLOGY 
• 188 breast carcinoma  patients were  randomly assigned to treatment or 
observation group each consisting of 94 patients after informed consent. 
Study period was  between October 2009 – November 2010 . 
• Patients were stratified according to age (less than 50 years,  50 years or 
older) , whether they receive concurrent chemoradiotherapy or not and 
metastatic or non-metastatic disease. 
• Treatment group patients  received  Gatifloxacin 400 mg OD from day 6 to 
day 14 of  each chemotherapy cycle.  
• When febrile neutropenia occurred , no  chemotherapy dose compromise in 
next cycle   was allowed except in  patients  complicated by life threatening 
infections. 
 Definition of Febrile neutropenia- A single oral temperature of greater than 
38.3°C (101°F) or 38.0°C or greater (100.4°F) for over 1 hour with ANC  
less than 500 mcL or less than 1,000 mcL with predicted rapid decline. 
• All febrile neutropenic patients were admitted in the hospital and started on 
broad spectrum antibiotics according to hospital protocol. 
• Decision on oral or IV antibiotic was decided by the treating physician based 
on age, PS, and clinical picture. It was continued till all signs of infection and 
fever disappeared. 
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• For all admitted patients chest Xray and blood culture was done. Total count  
\ Absolute Neutrophil count was done daily  till the count is non neutropenic. 
• Admitted patients were discharged from the hospital if afebrile for 2 days , no 
active infection or ANC >  500. 
• Decision on growth factors were taken by the discretion of treating phycisian 
on the basis of age, comorbids , severity of infection etc 
• Severe infection is defined as sepsis related syndrome , pneumonia, 
hypotension or death. 
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PATIENT SELECTION 
INCLUSION CRITERIA 
• Age > 20 years & < 70 years 
• PS – 0,1 
• Histologically proven invasive breast carcinoma. 
• Chemotherapy regimens 
Breast carcinoma  –  FEC  ( 5-Flurouracil, Epirubicin,Cyclophosphamide ), 
TE ( Taxol, Epirubicin ) with or with out concurrent radiotherapy ( 40 gy  ) 
  EXCLUSION CRITERIA 
• Poor Performance Status ( 2, 3, 4 ) 
• Compromised renal, hepatic, cardiac  function. 
• Pancytopenia due to bone marrow involvement. 
• Active infection / current antibacterial therapy. 
• Cerebral metastases. 
• Previous malignancy. 
• H/O epilepsy, uncontrolled Diabetis Mellitus. 
• Hemoglobin < 10 gm \ dl,. Total count < 4000. 
• H/O adverse reactions to Quinolones . 
• Previous chemotherapy / Radiotherapy 
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• Pregnancy and breast feeding. 
All patients had hemogram , renal function test ( blood urea , serum creatinine ) , 
liver function  test ( serum bilirubin, SGOT, SGPT, ALP ) , chest Xray, ECG, 
ECHO, US abdomen. 
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  PRIMARY END POINTS OF THE STUDY 
• Number  of febrile episodes. 
• Documented infection. 
• Culture positive infection. 
• Infection related mortality . 
SECONDARY END POINTS OF THE STUDY 
• Number of febrile episodes in first and then subsequent cycles. 
• Days of hospitalisation . 
• ICU admissions. 
• Requirement of intravenous antibiotics. 
• Isolation of organisms 
• Whether antibiotic prophylaxis was helpful   in elderly or patients with 
comorbids. 
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  STATISTICAL METHODS 
 
1. Chi- square test  of association and Z test of two proportions was employed  
to test the significance  of  incidence of febrile neutropenia and to compare it  
with various parameters like type of chemotherapy used, co-morbids, elderly 
age, metastatic disease, usage of antibiotics, hospitalisation infections and 
concurrent chemoradiotherapy. 
2. Randomnisation of patients into 2 groups such as arm A who receive Oral 
Gatifloxacin as antibiotic prophylaxis and arm B who did not receive any 
antibiotic prophylaxis was done using computerised minimisation algorithm. 
3. A sample size of 200 patients was required to demonstrate a absolute 
decrease in the risk of febrile neutropenia by 20% when patients are treated 
with prophylactic Gatifloxacin  with the statistical power of 80%. 
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 Risk Categorization of febrile neutropenic patients according to cancer  
institute protocol. 
Low Risk 
  Solid malignancy 
  Age < 60 years 
  No comorbid illness 
  No organ dysfunction 
Intermediate Risk 
  Solid malignancy with organ dysfunction  
  Age > 60 years 
  All hematological malignancies excluding AML/transplant patients 
 
High Risk 
  All transplant patients 
  AML induction 
 
Therapy :  
 Our current department policy recommends the following antibiotic(s) as 
emperic treatment according to risk categorisation prior to availability of the culture 
and sensitivity report :  
Low Risk 
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Levofloxacin + Co-Amoxy Clavulanate  
Intermediate Risk 
I line  -   Cefaperazone / Sulbactam+Amikacin  
II line -   Piperacillin / Tazobactam  
III line -   Meropenem / Imipenem  
High Risk 
I line -   Piperacillin / tazobactam  
II line -   Meropenam \ imipenam 
Vancomycin / Teicoplanin  included in Staphylococcus aureus infection suspected. If 
fever persist more than 4 to 5 days, then  antifungals are considered. 
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Gatifloxacin. 
 It is a 8- Methoxy Fluroquinolone. 
 It belongs to fourth generation quinolone family similar to 
Levofloxacin. 
 It inhibits DNA gyrase or Topoisomerase IV. 
 Absorbed well by the gastrointestinal tract with 96% bioavailability. 
It undergoes limited biotransformation and well distributed in the 
body. 70% of drug is excreted unchanged in the urine. 
 Available in tablet, injection and ophthalmic solution forms 
 Oral dosage  is 400 mg \ day. 
 Side effects- nausea, vomiting , diarrhea,  vaginitis,  dizziness, 
hyperglycemia, hypoglycemia, seizures, hallucinations, QT- 
prolongation syndrome. 
 Significant drug interactions occurs with Digoxin, Calcium carbonate, 
Warfarin, Theophylline, Anti Diabetic agents, Probenecid, Non 
steroidal anti inflammatory drugs. 
 It is one of the antibiotic used as monotherapy in low risk febrile 
neutropenia patients. 
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RESULTS 
 
A total of 188 breast carcinoma who met both inclusion and exclusion criteria were 
randomly assigned to treatment or observation group each consisting of 94 patients 
between November 2009- October 2010  
TABLE 1 
Base line characteristics of the patient 
 ARM A (AB ) ARM B ( no AB ) 
AGE 
 
< 50 
 
>50 
RANGE 
 
 
51(54.2%) 
 
43(45.7%) 
 
 
25-68 
 
 
53(56.3%) 
 
41(43.7%) 
 
 
29-68 
 
PS-0,1 
 
PS-2-4 
 
94(100%) 
 
0 
 
94(100%) 
 
0 
 
Chemotherapy 
FEC 
Taxol\Epirubicin 
 
 
81(86.1%) 
13(13.9%) 
 
 
 
84(89.3%) 
10(10.7%) 
 
Concurrent RT 
Yes 
No 
 
 
 
53(56.3%) 
41(43.7%) 
 
 
 
 
51(54.2%) 
43(45.7%) 
 
Stage 
 
Metastatic 
 
Non- Metastatic 
 
 
 
11(10.8%) 
 
83(88.2%) 
 
 
 
 
8(8.6%) 
 
86(91.4%) 
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Co-Morbids 
 
HT 
 
DM 
 
IHD 
 
 
18(19.1%) 
 
7 (7.4%%) 
 
5 (5.3%) 
 
 
19(20.2%) 
 
9(9.5%) 
 
1(1%) 
 
Of the 94 patients in the antibiotic arm, 51(54.2%) patients were less than 50 
years of age and 43(45.7%) were above 50 years of age and in the control group 
which did not receive antibiotics group almost similar distribution was seen where 
53 (56.3%) patients were less than 50 years of age and 41(43.7%) of them were 
above 50 years of age. The range was almost similar in both the groups ie 25 -68 in 
the antibiotics group and 29 -68 in the control group. 
All the patients in both the groups had performance status of 0 -1. 
Two types of chemotherapy were employed according to the needs of the 
patients. In the antibiotics group  81(86.1%)  patients received FEC chemotherapy 
whereas 13(13.9%) patients received taxol / epirubicin.  Similar pattern was seen in 
the control group where 84(89.3%) patients received FEC chemotherapy and 10 
(10.7%) patients received taxol / epirubicin chemotherapy. 
As the sample is derived from a heterogenous population, concurrent 
radiotherapy was given to 53 (56.3%) patients in the antibiotic group and 51 (54.2%) 
patients in the control group. The remaining patients in both the groups did not 
receive concurrent radiotherapy. 
Majority of the patients ie 83 (88.2%) patients in the antibiotic group and 86 
(91.4%) patients in the control group had non –metastatic disease. Only 11(10.8%) 
36 
 
patients in the antibiotic group and 8 (8.6%) patients in the control group had 
metastatic disease. 
The incidence of co-morbids such as hypertension and diabetes mellitus were 
almost similar in both the groups 18(19.1%) vs `19(20.2%) and 7(7.4%) vs 9(9.5%) 
respectively. However Ischemic heart disease (IHD) was seen in 5 (5.3%) patients in 
the antibiotic group whereas only 1 patient had IHD in the control group. 
TABLE 2 
Incidence of Febrile neutropenia 
 
Febrile 
Neutropenia 
Arm A (Ab ) Arm B ( No Ab ) P Value 
In first cycle (94 
cycles) 
5(5.31%) 15(15.95%) 0.031 
( significant) 
In 2-6 cycles (470 
cycles) 
13(2.76%) 26(5.53%) 0.048 
( significant) 
In all cycles (564) 18(3.19%) 41(7.26%) 0.04 
( significant) 
 
Incidence of neutropenia in the first cycle was seen three times more in the 
control group than the antibiotic group as 15 episodes(15.95%) occurred in the 
control group  when compared to 5 episodes (5.31%) in the antibiotic group. 
However in the subsequent 2
nd
 to 6 cycles of chemotherapy 26 (5.53) episodes of 
febrile neutropenia were observed in the control group compared to 13 (2.76%) 
episodes in the antibiotic group. Total episodes of febrile neutropenia was also 
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almost two times higher in patients in the control group than patients in the antibiotic 
group (41  vs 18 ). All these observations were found to be statistically significant. 
TABLE 3 
Chemotherapy and febrile neutropenia 
FEC CHEMOTHERAPY 
 ARM A (AB ) ARM B ( no AB ) p value 
No. of patients 81 84  
No. cycles received 486 504 P=0.05 
(Significant) FN  episodes  14(2.88%) 39(7.73%) 
 
In the antibiotics group 81(86.1%) patients received FEC chemotherapy  (486 
cycles)  and 84(89.3%) patients received FEC chemotherapy ( 504 cycles ) in the 
control group. Incidence of febrile neutropenia was seen less in antibiotics group ie 
14 episodes (2.88%) compared to 39 episodes (7.73%) in the control group which 
was statistically significant.(P = 0.05) 
TAXOL / EPIRUBICIN 
 ARM A (AB ) ARM B ( no AB ) p value 
     No. of patients 13 10  
No. cycles received 78 60 
P=0.69 
(Not Significant) 
FN  episodes 
observed 
4(5.12%) 2(3.33) 
 
13 patients received taxol/epirubicin in the antibiotics group whereas 10 
patients received in the control group. Here slightly more incidence of febrile 
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neutropenia was seen in antibiotics group than in control group (4 episodes (5.12%) 
vs 2 episodes(3.33%).However this result was not statistically significant. 
TABLE 4 
Comorbids and febrile neutropenia 
 ARM A (AB ) ARM B ( no AB ) p value 
No. of patients 30 29  
1.0 
 (Not significant) 
No. cycles received 180 174 
 
FN  episodes  
 
6 (3.33%) 
 
6 (3.4%) 
 
Similar number of patients had comorbid disease in both the antibiotic group and 
control group (30 vs 29 patients) and incidence of febrile neutropenia was also the 
same in both the groups with 6 episodes in each group which was not statistically 
significant. 
TABLE 5 
Concurrent RT \ CT and febrile neutropenia 
 ARM A (AB ) ARM B ( no AB ) p value 
Received RT 53 51 0.1 
( not significant) No. cycles received 318 306 
Had FN 15(4.71%) 25(8.16%) 
 
Though almost similar number of patients underwent concurrent CT/RT in 
antibiotics group and control group (53 vs 51 patients) incidence of febrile 
neutropenia was higher by 1.5 times in the control group than antibiotics group 
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(15 (4.71%) episodes vs 25 (8.16%) episodes).However it was not statistically 
significant. 
 
TABLE 6 
Metastatatic disease and febrile neutropenia  
Febrile Neutropenia ARM A (AB ) ARM B ( no AB ) p value 
Metastatic disease 11 8  
0.07 
(Not significant) 
No. cycles received 66 48 
Had FN 1(1.51%) 3(6.2%) 
 
11 patients in the antibiotic group and 8 patients in the control group had 
metastatic disease. 1 episode of febrile neutropenia was observed in the 66 cycles 
of chemotherapy given to patients in antibiotic group whereas 3 episodes of 
febrile neutropenia was seen in 48 episodes of chemotherapy given to the control 
group patients which was also not statistically significant 
TABLE 7 
Hospitalization due to febrile neutropenia 
No. of hospitalization ARM A (AB ) ARM B ( no AB ) P value 
In first cycle 5 15 0.031 
In 2-6 cycles 13 26 0.048 
In all cycles 18 41 0.04 
Median Duration of 
Admission (in days) 
5 5 - 
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In first cycle 5 5  
In 2-6 cycles 5 5  
ICU Admission 1 4 0.07(not 
significant) 
 
Incidence of patients requiring hospitalization in first cycle  was three times 
higher in the control group when compared with hospitalisation in antibiotics group 
which was statistically significant (15 vs 5).  In the subsequent cycles incidence of 
febrile neutropenia was double the time more in the control group than the antibiotic 
group (26 vs 13) . Total incidences of hospitalization were also higher in the control 
group than the antibiotic group (18 vs 41) which was statistically significant. One 
patient had life threatening diarrhoea and  three more patients had pneumonia  
requiring ICU admission in placebo group  where as only one patient in antibiotic  
group had admission in ICU for pneumonia which was also not statistically 
significant. 
However the median duration of hospitalization remained the same ie 5 days 
in both the control group and antibiotic group during the 1
st
 cycle and the subsequent 
cycles of chemotherapy. 
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TABLE 8 
Frequency of Antibiotic Usage 
Frequency of AB 
usage 
ARM A (AB ) ARM B ( no AB ) 
In first cycle  
Oral AB 2 4 
IV AB 3 11 
In 2-6 cycles 
Oral AB 5 10 
IV AB 8 16 
Median usage(in days) 5 5 
Total Frequency of IV 
AB usage (564 cycles) 
11 27 P value 
0.0078 
Significant 
 
In the first cycle of chemotherapy 2 patients in the antibiotic group and 4 
patients in the control group were given oral antibiotics while 11 patients in the 
control group were administered intravenous antibiotics and 3 patients in the 
antibiotic group were administered IV antibiotics. 
In the subsequent cycles 5 patients were given oral antibiotics in the 
antibiotic group as compared to 10 patients in the control group. However 8 patients 
in the antibiotic group required intravenous antibiotics when compared to 16 patients 
in the control group requiring intravenous antibiotics. 
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However the median duration of antibiotic usage remained the same in both 
the groups ie 5 days. Total frequency of intravenous antibiotic usage remained 
higher in control group than the antibiotic group (27 vs 11). 
TABLE 9 
Clinically documented infection (Probable) 
 ARM A (AB ) ARM B ( no AB ) 
Mucositis ( grade III ) 3 4 
Respiratory tract 
infection 
3 6 
Diarrhoea 2 3 
IV cannula infection 1 2 
Total 9(50%) 15(36.5%) 
 
Grade III mucositis and diarrhoea was seen almost similar in the antibiotic and 
control group (3 vs 4 and 2 vs 3 respectively).But respiratory tract infection and 
IV cannula infection were two times more common in the control group when 
compared with antibiotic group.(6 vs 3 and 2 vs 1 respectively). The observed 
incidence of clinically documented infection is more in antibiotic group than in 
observational group (50% vs 36.5%). 
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TABLE 10 
Blood culture positivity documented in febrile neutropenic episodes. 
ARM A (16.6%) 
Of 18 episodes 
ARM B (9.7%) 
Of 41 episodes 
Klebsiella pneumonia -1 
Esherichia coli -1 
Streptococcus pyogenes- 1 
Streptococcus pyogenes- 2 
Pseudomonas aeruginosa -1 
Klebsiella pneumonia- 1 
 
Blood culture positivity of organisms was seen in 16.6% and 9.7% of febrile 
neutropenic episodes in antibiotic and placebo groups respectively. Klebsiella 
pneumonia was found in one patient each in both groups whereas Streptococcus 
pyogenes was seen in 1 patient in antibiotic group and in 2 patients in the control 
group. Additionally Escherichia coli was seen only in the antibiotic group and 
Pseudomonas aeruginosa was seen exclusively only in the control group in one 
patients each. Out of 188 treated patients 1 patient developed hypoglycaemia and 2 
patients developed hyperglycemia as a result of gatifloxacin toxicity. 
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RESULTS 
 
Figure 1 :Incidence of  febrile neutropenia 
 
Figure 2 : FEC Chemotherapy and febrile neutropenia 
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Figure 3 : TAXOL / EPIRUBICIN Chemotherapy And Febrile Neutropenia 
 
 
 Figure 4 : Comorbids and febrile neutropenia 
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Figure 5 : Concurrent RT \ CT and febrile neutropenia 
 
Figure 6 : Metastatatic disease and febrile neutropenia  
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Figure 7 : Frequency of Antibiotic Usage 
 
 
Figure 7 A :Total Frequency Of IV Antibiotic Usage 
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Figure 8 : Clinically documented infection (Probable) 
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DISCUSSION 
                Our  study evaluated the role of primary prophylaxis of antibiotics in  post 
chemotherapy breast carcinoma patients. The incidence of febrile neutropenia in first 
cycle is considerably less in antibiotic group.  Henri et al
6
 noted 8.2% incidence of 
FN with FEC  chemotherapy in breast carcinoma patients  where as Gianni et al
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noted 20% in paclitaxol-adriamycin combination chemotherapy.  
                              
                             Cullen et al
38
 stated that there would be higher incidence of FN in 
first cycle than rest of the cycles. In his study with Levofloxacin prophylaxis in both 
solid tumours and lymphoma patients the incidence of FN was 3.8% in first where as 
it was 8% in rest of the  cycles.. In our study incidence of FN in first cycle is 5.3% 
and 15%  in antibiotic and placebo group and the incidence is  less in subsequent 
cycles in both antibiotic and placebo group ie., 2.7% and 5.5%. The protective effect 
of  antibiotic is  3 times more effective  in first cycle and it is statistically significant  
where it is only 2 times in rest of the cycles which is also  statistically significant 
.The declining trend of FN in subsequent cycles may be due to cytoreduction of 
tumour and improvement in immunity. The first cycle febrile neutropenia is more 
important, as more care and precautions would be taken for these group of patients in 
rest of the cycles . Prophylactic Gatifloxacin decreases the overall incidence of 
febrile neutropenia by more than 50%.  
           
Analysing the incidence of FN in FEC combination chemotherapy separately 
it  was  2.88% and 7.73% respectively in antibiotic  and placebo  groups respectively 
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where as the incidence quoted in PACS trial
6
 was around  8.4% which was almost 
similar to our placebo group. In the same study with FEC 3 cycles followed by  3 
cycles of Docetaxol , the incidence of FN was 11.2% where as David et
 53
 al had 
observed 16% incidence of FN in their study using Taxol-Epirubicin combination as 
neoadjuvant chemotherapy. In our study observed incidence of FN in TE 
combination chemotherapy was 5.12% and 3.33% in antibiotic and placebo groups 
which was not statistically significant. The lesser incidence of FN in TE subgroup 
could be attributed to lesser number of patients received TE. Thus our result could 
not be taken as a conclusive one. 
                          
             The incidence of hospital admission in our  study  was 5.3% and 
15.9% in antibiotic  and placebo groups respectively  in first cycle where as it was 
2.76% and  5.53% in subsequent cycles. As the benefit of prophylactic antibiotics in 
decreasing febrile neutropenia was more in first cycle , similar benefit for hospital 
admission was seen in first cycle. Cullen et al
38
 had observed , the incidence of 
hospital admission was 15.7% and 21.6% respectively in levofloxacin and placebo 
group respectively. Reduction in the incidence of hospitalisation  by antibiotic was 
statistically significant in first cycle , where as it was not significant in subsequent 
cycles.  Cullen et al
 38
 had stated that the  risk reduction of hospitalisation is 36% in 
first cycle where as it was only  27% in subsequent cycles .Same results were also 
obtained by Heijnen et al 
41
 , on using roxithromycin and ciprofloxacin  in small cell 
lung carcinoma patients , he had observed 17% and 31% incidence of hospitalisation 
with antibiotic and placebo groups respectively. Median days of hospital admission 
due to febrile neutropenia observed by the same authors  was 4 and 5 days 
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respectively . But against this study , in our study median days of hospital admission 
was similar in both arms ie., 5 days . In this study there was almost 50% reduction of 
hospitalisation with prophylactic antibiotics across all cycles. Decrease in 
hospitalisation cuts the extra cost due to hospitalisation and also decreases the 
exposure to cross resistant organisms. 
    
Clinically documented infections was observed in 9 out of 18 patients  (50%)  
and 15 out of 41 patients (36.5%)  in  antibiotic and placebo groups respectively. 
Cullen et  al 
38
 had observed  the following infections  upper respiratory tract 24.7%, 
lower respiratory tract 12.9%,skin  (10.5%), and urinary tract (8.3%) in febrile 
neutropenia .   Heijhen et al
 41
 in their study on the prophylactic role of antibiotics by 
using Ciprofloxacin and Roxithromycin had observed more clinical documentation 
of infection in placebo group than antibiotics group where as in our study it was 
antibiotic group which had more clinical documentation of infection. Also in their 
study incidence of respiratory  and GIT infection was almost reduced to half in 
antibiotic group patients. Usually pneumonia in a neutropenic patients was 
associated with high mortality. In our study there was 50% decrease in  respiratory 
tract infections in placebo group.  
               
 One patient had life threatening diarrhoea and three more patients had 
pneumonia  requiring ICU admission in placebo group  where as only one patient in 
antibiotic  group had admission in ICU for pneumonia. So ICU admissions are 
reduced considerably in antibiotic group. Heijhen et al
41
 in their study had 
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documented 6% and  2% ICU admission in placebo and antibiotic group 
respectively.Median number of ICU admission was 7 and 2 days where as in our 
study it was 4 days in both study groups. All the patients except  one  who had ICU 
admissions had grade IV neutropenia. 
             
        One of the main goal of antibiotic prophylaxis was to decrease the 
morbidity due to myelosuppression in elderly  patients or patients with comorbids 
like systemic hypertension, ischemic heart disease , Diabetis mellitus etc.  our study 
was a negative study which have not shown any benefit  of antibiotic prophylaxis in 
patients with comorbids.But in elderly patients ie., age > 50 there was considerable 
reduction in the incidence of febrile neutropenia with antibiotics. 
          
There was not much literature available on the role of antibiotic prophylaxis 
in concurrent chemoradiotherapy in breast carcinoma patients .Various studies 
mentions the incidence of dermal , haematological and cardiac toxicity was more in 
concurrent chemoradiotherapy  than sequential therapy. Rouesse et al
 54
  in their 
study on adjuvant therapy in node positive breast cancer using sequential chemo-
radiotherapy  or concurrent chemo-radiotherapy  observed the incidence of gradeIII \ 
IV neutropenia and febrile neutropenia  was more in concurrent chemo-RT arm. In 
our study the incidence of FN was 4.71% and 8.16% in antibiotic and placebo arms 
respectively . The usage of antibiotic prophylaxis had decreased the incidence of 
febrile neutropenia by almost 50% in concurrent chemoRT . 
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 Blood culture positivity  documented in 18 and 41 febrile neutropenic 
patients in antibiotic and placebo groups in our study was 16.6%% and 9.7 % 
respectively where as  Cullen et.al
 38
  in their study had documented culture 
positivity in 4.6% and 12.6% .Contrary to Cullen’s study we had more culture 
positivity in antibiotic group.  Out of the seven documented infection , 4 was gram 
negative where as 3 was gram positive. Kanamaru et al
55
 in their study had 
mentioned commonest isolate from blood  in febrile neutropenic patients was   gram 
positive organisms ie., Staphylococcus species in 22% followed by Pseudomonas 
aeruginosa in 11.6%  . In our study we had more gram negative than gram positive 
organisms. Commonest organism isolated is Streptococcus pyogenes followed by 
Klebsiella pneumonia and Esherichia coli. We had no documented fungal infection. 
 
One of the main purpose of employing antibiotic prophylaxis to prevent 
febrile neutropenia in patients receiving chemotherapy is to decrease the incidence of 
infection related mortality. Most of the trials conducted have shown a decrease in 
infection related mortality in patients receiving anti biotic prophylaxis. Gafter et al
45 
in his meta-analysis observed that fluoroquinolone prophylaxis reduced the risk for 
death by 48% (CI, 33% to 65%) and infection-related death by 62% (CI, 31% to 
79%). Mario Cruciani 
48
  in his meta analysis comparing the benefit of addition of 
gram-positive prophylaxis to fluoroquinolone in neutropenic patients also found that 
antibiotic prophylaxis does decrease the mortality rate  but found no significant 
effect of the addition of gram positive prophylaxis to quinolone in terms of infection 
related mortality. (RR, 0.95; 95% CI, 0.53 to 1.71). Reuter et al
44
 in their prospective 
observational study observed a significantly higher rate of mortality(33%) on 
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discontinuation of levofloxacin when compared with that of routine fluroquinolone 
prophylaxis.(2.9%).Also w hen levofloxacin was reintroduced the mortality rate was 
comparable to those period of routine levofloxacin prophylaxis. In contrary in our 
study  there was no infection related mortality   in both the groups. 
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Limitations Of  The Study 
1. In this study  , even though number of localised and metastatic disease 
patients  in both arms were equal ,patients  were not stratified by exact breast 
carcinoma staging. 
2. No defined criteria for the use of colony stimulating factors ,mainly it was 
decided on  the basis of treating phycisians discretion . It was not taken in to 
account for analysis. 
3. Dose intensity of chemotherapy was not analysed. 
4. It is possible some associations mentioned in this study may have occurred 
by chance. There is some possibility , unknown variables may have 
confounded the results. 
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 Summary and Conclusion 
              This study is an attempt to assess the clinical evidence supporting the 
efficacy of antibiotic prophylaxis with fluoroquinolones in neutropenic cancer 
patients. 188 breast carcinoma patients were randomly assigned to treatment or 
observation group each consisting of 94 patients. Treatment group patients received 
Gatifloxacin 400 mg OD from day 6 to day 14 of each chemotherapy cycle.  Patients 
who developed febrile neutropenia  were admitted in the hospital and oral or IV 
antibiotics were administered based on age, PS and clinical picture of patients. 
Primary end points of the study were the number of febrile episodes, documented 
infection, culture positive infection, infection related mortality while the secondary 
end points of the study include number of febrile episodes in first and then 
subsequent cycles, days of hospitalisation ,  ICU admissions, requirement of 
intravenous antibiotics, isolation of organisms, whether antibiotic prophylaxis 
helpful   in elderly or patients with comorbids. 
• The incidence of febrile neutropenia in first cycle is considerably less in 
antibiotic group. The protective effect of  antibiotic is  3 times more effective  
in first cycle and it is statistically significant  where it is only 2 times in rest 
of the cycles which is not statistically significant. The incidence of hospital 
admission in our study  was 5.3% and 15.9% in antibiotic  and placebo 
groups respectively  in first cycle where as it was 2.76% and  5.53% in 
subsequent cycles .In our study median days of hospital admission was 
similar in both arms ie., 5 days . In this study there was almost 50% reduction 
of hospitalisation with prophylactic antibiotics across all cycles. Clinically 
documented infections was observed in 9 out of 18 patients  (50%)  and 15 
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out of 41 patients (36.5%)  in  antibiotic and placebo groups respectively.One 
patient had life threatening diarrhoea and three more patients had pneumonia  
requiring ICU admission in placebo group  where as only one patient in 
antibiotic  group had admission in ICU for pneumonia. So ICU admissions 
are reduced considerably in antibiotic group. 
Conclusions drawn from this study include 
 Incidence of febrile neutropenia is decreased in patients who received 
gatifloxacin  and this effect was seen considerably more in the first cycle of 
chemotherapy than the subsequent cycles. 
 Incidence of hospitalization due to febrile neutropenia was also less in 
patients receiving antibiotic prophylaxis .However median duration of 
hospitalization of patients remained the same irrespective of antibiotic 
prophylaxis or not. 
 Antibiotic prophylaxis also reduced the need of intravenous antibiotics in 
patients with febrile neutropenia. 
 Clinically and microbiologically documented infection  was not decreased 
with the use of antibiotic prophylaxis 
 Antibiotic prophylaxis did not exert additional positive effect in patients with 
comorbid condition and in patients with metastatic disease. 
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                                                            PROFORMA 
 
Name:                                                                                                       Stage 
OP No:                                                                                                       T  - 1 / 2 /3 
/4 
Index No:                                                                                                   N- 1 / 2 /3  
Age :                                                                                                           M- 0 / 1 
 Sex:                                                                                                            ER – 1 / 2 
PS:                    Ht:                   Wt:                   BSA :                                PR – 1 / 2 
I. COMORBIDS                                                                                          HER – 1 / 2 
 1. HT              - 1   / 2                                                                               GRADE- 1 / 2 
/ 3 
2. DM                1   / 2                                                                               NEOADJ / 
ADJ CT 
3. IHD 1   / 2                             CT SCHEDULE – (FEC,  TE) – 1 / 2 / 3 
4. Others                                                   CONCURR CT /RT – 1 / 2 
1st Cycle – Date  
Nadir TC                                                   Hos Admn: 1 / 2                          Fever: 1 / 
2 
ICU – 1 / 2                            Pneumonia : 1 / 2                   Hypoten : 1 / 2                   
Others: 
ORAB/ IVAB – 1 / 2             IInd line AB – 1 / 2             Days of AB:                     
Days of Admn: 
2nd  Cycle – Date  
Nadir TC                                                   Hos Admn: 1 / 2                          Fever: 1 / 
2 
ICU – 1 / 2                            Pneumonia : 1 / 2                   Hypoten : 1 / 2                   
Others: 
ORAB/ IVAB – 1 / 2             IInd line AB – 1 / 2             Days of AB:                     
Days of Admn: 
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3rd Cycle – Date  
Nadir TC                                                   Hos Admn: 1 / 2                          Fever: 1 / 
2 
ICU – 1 / 2                            Pneumonia : 1 / 2                   Hypoten : 1 / 2                   
Others: 
ORAB/ IVAB – 1 / 2             IInd line AB – 1 / 2             Days of AB:                     
Days of Admn: 
4th Cycle – Date  
Nadir TC                                                   Hos Admn: 1 / 2                          Fever: 1 / 
2 
ICU – 1 / 2                            Pneumonia : 1 / 2                   Hypoten : 1 / 2                   
Others: 
ORAB/ IVAB – 1 / 2             IInd line AB – 1 / 2             Days of AB:                     
Days of Admn: 
5th Cycle – Date  
Nadir TC                                                   Hos Admn: 1 / 2                          Fever: 1 / 
2 
ICU – 1 / 2                            Pneumonia : 1 / 2                   Hypoten : 1 / 2                   
Others: 
ORAB/ IVAB – 1 / 2             IInd line AB – 1 / 2             Days of AB:                     
Days of Admn: 
6th Cycle – Date  
Nadir TC                                                   Hos Admn: 1 / 2                          Fever: 1 / 
2 
ICU – 1 / 2                            Pneumonia : 1 / 2                   Hypoten : 1 / 2                   
Others: 
ORAB/ IVAB – 1 / 2             IInd line AB – 1 / 2             Days of AB:                     
Days of Admn: 
 
 
 
